2010
Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug And Alcohol Dependence 2010, 112: 1-8. PMID: 20561758, PMCID: PMC2946976, DOI: 10.1016/j.drugalcdep.2010.04.021.Peer-Reviewed Original ResearchConceptsPlacebo groupStudy completersNaltrexone doseClinical trialsContinuous abstinenceOral naltrexone treatmentNicotine patch therapyNicotine replacement therapyInteractive voice responseRandomized clinical trialsMenstrual cycle statusEffect of doseNaltrexone augmentationNaltrexone groupAdverse eventsNaltrexone treatmentNicotine patchPatch therapyReplacement therapyQuit dayWeek 1AbstinenceDoseWomenLess adherent
1988
Antidepressant activity of 2‐hydroxydesipramine
Nelson J, Mazure C, Jatlow P. Antidepressant activity of 2‐hydroxydesipramine. Clinical Pharmacology & Therapeutics 1988, 44: 283-288. PMID: 3416551, DOI: 10.1038/clpt.1988.151.Peer-Reviewed Original ResearchConceptsPlasma levelsOH-DMIAntidepressant activityDSM-III major depressionDMI levelsSteady-state plasma levelsWeeks of hospitalizationDrug plasma levelsFixed-dose protocolTotal drug levelsMajor depressionDrug levelsParent drugMeasure of responseTrialsResponsePrior studiesHospitalizationLevelsMedicationsPatientsInpatientsNonpsychoticDoseWeeks